Evidence map›Paper›PMID 40431653›Full record

ReviewViruses2025

Human Microglia Models for NeuroHIV.

Priyanka Sarkar, Xu Wang, Wenhui Hu, Jian Zhu, Wen-Zhe Ho

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Methamphetamine enhances HIV infection of human iPSC-derived microglia.NeuroImmune pharmacology and therapeutics · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Priyanka SarkarDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.ORCID 0000-0003-1798-1469
Xu WangDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.
Wenhui HuDepartment of Neuroscience, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0001-8152-6116
Jian ZhuDepartment of Pathology, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Wen-Zhe HoDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.ORCID 0000-0002-5235-0606

Funding

CD4 T cell-targeted nanoparticle in vivo delivery of CRISPR/Cas9 genome editors for HIV cureR01AI145034 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI HU, WENHUI · 2019 to 2023
$3.8M
HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral OrganoidsR01DA051893 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI HO, WENZHE, HU, WENHUI · 2020 to 2024
$3.1M
Long-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIVR01DA056876 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu · 2022 to 2026
$3.0M
Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine UsersR01DA059538 · NIDA · OHIO STATE UNIVERSITY · PI Wei Jiang, Jian Zhu · 2023 to 2026
$2.9M
Synthetic fentanyls adversely affect the blood-brain barrier and HIV replication in the context of neuroHIVR01DA058536 · NIDA · UNIVERSITY OF FLORIDA · PI Allison Michelle Andrews, WENZHE HO · 2023 to 2026
$2.8M
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in MicrogliaR01MH134402 · NIMH · OHIO STATE UNIVERSITY · PI HO, WENZHE, ZHU, JIAN · 2023 to 2025
$2.2M
Antagonize Host Survival and Immune Escape Mechanisms for Elimination of HIV Viral ReservoirsR56AI181631 · NIAID · OHIO STATE UNIVERSITY · PI LING, BINHUA "JULIE", ZHU, JIAN · 2024 to 2024
$842k
NIAID NIH HHS R01 AI145034NIAID NIH HHS R56 AI181631NIDA NIH HHS R01 DA051893NIDA NIH HHS R01 DA056876NIDA NIH HHS R01 DA058536NIDA NIH HHS R01 DA059538NIH HHS DA051893, DA058536 and MH134402NIMH NIH HHS R01 MH134402
6 · The paper itself

Abstract

Microglia are the primary target and reservoir of HIV infection in the central nervous system (CNS), which contributes to HIV-associated neurocognitive disorder (HAND). However, studying HIV infection of microglia has been challenged by the limited availability of primary human microglial cells. To overcome this issue, investigators have developed various microglial models for HIV studies, including immortalized human microglial cell lines, HIV latently infected microglial clones, peripheral blood monocyte-derived microglia (MMG), induced pluripotent stem cell (iPSC)-derived microglia (iMg), and microglia-containing cerebral organoids (MCOs) from iPSCs. Though these models have been used in many laboratories, the published data about their expression of the specific human microglia markers and the HIV entry receptors are conflicting. In addition, there is limited information about their feasibility and applicability as a suitable model for acute and/or latent HIV infection. This review provides a concise summary of the currently used human microglial models, with a focus on their suitability for NeuroHIV research.

Indexed as

HIV-1HIV InfectionsMicrogliaCell LineHumansInduced Pluripotent Stem CellsOrganoidsHIVinduced pluripotent stem cell (iPSC)-derived microglia (iMg)microgliamicroglia-containing cerebral organoids (MCOs) from iPSCsperipheral blood monocyte-derived microglia (MMG)

Identifiers

PMID40431653
PMCPMC12116007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.